510(k) Report

510(k) · Cleared

Cleared

LZI Fentanyl III Enzyme Immunoassay

K251634510(k) SpecialCleared Jun 18, 202520-day reviewClass II21 CFR 862.3650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Lin-Zhi International, Inc. · DJG Enzyme Immunoassay, Opiates

Cleared on Jun 18, 2025 as substantially equivalent to K201938 (Lin-Zhi International, Inc., 2020) after a 20-day review. Its family tree reaches back 6 generations to 2000.

Decided
Jun 18, 2025
Review
20 days
Class
Class II
Product code
DJG
Recalls
None
Predicates
1

Its longest line of descent runs back 6 generations to K001178 (2000). No later device cites it as a predicate yet.

  1. Root · 6 generations backK001178 Cedia Dau 6-Acetylmorphine AssayMicrogenics Corp. · 2000
  2. 5 generations backK040316 Cedia Buprenorphine AssayMicrogenics Corp. · 2004
  3. 4 generations backK150606 Emit II Plus Buprenorphine Assay, Emit II Plus Specialty Drug…Siemens Healthcare Diagnostics, Inc. · 2015
  4. 3 generations backK161216 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis…Immunalysis Corporation · 2017
  5. 2 generations backK181159 LZI Fentanyl Enzyme ImmunoassayLin-Zhi International, Inc. · 2018
  6. 1 generation backK201938 LZI Fentanyl II Enzyme ImmunoassayLin-Zhi International, Inc. · 2020
  7. This deviceK251634 LZI Fentanyl III Enzyme ImmunoassayLin-Zhi International, Inc. · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−6K001178Cedia Dau 6-Acetylmorphine AssayMicrogenics Corp.2000—
−5K040316Cedia Buprenorphine AssayMicrogenics Corp.2004—
−4K150606Emit II Plus Buprenorphine Assay, Emit II Plus Specialty Drug…Siemens Healthcare Diagnostics, Inc.2015—
−3K161216Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis Fentanyl…Immunalysis Corporation2017—
−2K181159LZI Fentanyl Enzyme ImmunoassayLin-Zhi International, Inc.2018—
−1K201938LZI Fentanyl II Enzyme ImmunoassayLin-Zhi International, Inc.2020—
0 (this device)K251634LZI Fentanyl III Enzyme ImmunoassayLin-Zhi International, Inc.2025—
FIG. 1 — Lineage of K251634, 2000–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DJG device

  1. #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K201938LZI Fentanyl II Enzyme Immunoassay
Summary page 6
…nzyme Immunoassay. The purpose of this application is to support modifications nzyme Immunoassay (k201938). These modifications include a change in target analyte from norfentanyl to fentanyl, an updated cutoff concentration, and chan…
Lin-Zhi International, Inc.2020—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 25 years and passes through 4 companies; a new generation was cleared every 4.0 years on median.
  • None of the 6 ancestors has a recall.

How does its category compare?

All DJG devices

DJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · DJG

3in 2025

2007: 22008: 22009: 22010: 62011: 62012: 52013: 52014: 92015: 122016: 22017: 42018: 52019: 32020: 52021: 32022: 22023: 102024: 52025: 32026 (partial year): 3
2007high 12 (2015) · low 2 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DJG

31in 2025

2010: 187 days median2011: 233 days median2012: 95 days median2013: 60 days median2014: 62 days median2015: 141 days median2017: 101 days median2018: 134 days median2019: 235 days median2020: 30 days median2021: 422 days median2023: 140 days median2024: 150 days median2025: 31 days median2026 (partial year): 157 days median
2007high 422 (2021) · low 30 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DJG

2in 2025

2011: 12019: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DJG

1in 2025

2011: 42012: 12013: 42015: 32016: 22017: 12018: 12021: 22022: 12024: 32025: 1
2007high 4 (2011) · low 0 (2007)2025

MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—00
2010618700
2011623314
201259501
201356004
201496200
20151214103
20162—02
2017410101
2018513401
2019323510
202053000
2021342202
20222—01
20231014000
2024515003
202533121
202631570—

What is it indicated for?

The LZI Fentanyl III Enzyme Immunoassay is intended for the qualitative determination of fentanyl in human urine at the cutoff value of 1 ng/mL when calibrated against fentanyl. The assay is designed for prescription use with a number of automated clinical chemistry analyzers.

The assay provides only a preliminary analytical result. A more specific alternative chemical method (e.g., gas or liquid chromatography and mass spectrometry) must be used in order to obtain a confirmed analytical result. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K251634: LZI Fentanyl III Enzyme Immunoassay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K251634

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026